SZL-P1-41 | CAS#222716-34-9 | Skp2 inhibitor

MedKoo Cat#: 562992 | Name: SZL-P1-41

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SZL-P1-41 is a Skp2 inhibitor. It acts by selectively suppressing Skp2 SCF E3 ligase activity.

Chemical Structure

SZL-P1-41

CAS#222716-34-9

Theoretical Analysis

MedKoo Cat#: 562992

Name: SZL-P1-41

CAS#: 222716-34-9

Chemical Formula: C24H24N2O3S

Exact Mass: 420.1508

Molecular Weight: 420.52

Elemental Analysis: C, 68.55; H, 5.75; N, 6.66; O, 11.41; S, 7.62

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,350.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SZL-P1-41; SZL P1 41; SZLP141; SKP2 E3 Ligase Inhibitor III; SZLP-141; SZLP 141;

IUPAC/Chemical Name

3-(2-Benzothiazolyl)-6-ethyl-7-hydroxy-8-(1-piperidinylmethyl)-4H-1-benzopyran-4-one

InChi Key

JKIXLEKBXHMXTN-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H24N2O3S/c1-2-15-12-16-22(28)18(24-25-19-8-4-5-9-20(19)30-24)14-29-23(16)17(21(15)27)13-26-10-6-3-7-11-26/h4-5,8-9,12,14,27H,2-3,6-7,10-11,13H2,1H3

SMILES Code

O=C1C(C2=NC3=CC=CC=C3S2)=COC4=C(CN5CCCCC5)C(O)=C(CC)C=C14

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 420.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Park JU, Jo JH, Kim S, Redon CE, Aladjem MI, Seo Y, Jang SJ, Jang SM. RepID as a potential biomarker and therapeutic target for lung neuroendocrine tumor. Sci Rep. 2024 Nov 11;14(1):27487. doi: 10.1038/s41598-024-79104-9. PMID: 39523440. 2: Brown LK, Kanagasabai T, Li G, Celada SI, Rumph JT, Adunyah SE, Stewart LV, Chen Z. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Prostate. 2024 Jun;84(9):877-887. doi: 10.1002/pros.24706. Epub 2024 Apr 11. PMID: 38605532. 3: Xie L, Liao J, Liu W, Wang R, Li X, Li W, Zhou Z. Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis. Cell Death Discov. 2023 Oct 2;9(1):364. doi: 10.1038/s41420-023-01648-y. PMID: 37779163; PMCID: PMC10543462. 4: Celada SI, Li G, Celada LJ, Lu W, Kanagasabai T, Feng W, Cao Z, Salsabeel N, Mao N, Brown LK, Mark ZA, Izban MG, Ballard BR, Zhou X, Adunyah SE, Matusik RJ, Wang X, Chen Z. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer. Mol Oncol. 2023 Oct;17(10):2126-2146. doi: 10.1002/1878-0261.13497. Epub 2023 Aug 21. PMID: 37491794; PMCID: PMC10552895. 5: Li P, Chen T, Kuang P, Liu F, Li Z, Liu F, Wang Y, Zhang W, Cai X. Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality. Cell Death Dis. 2022 Jul 13;13(7):606. doi: 10.1038/s41419-022-04973-9. PMID: 35831273; PMCID: PMC9279325. 6: Manafi Shabestari R, Chegeni R, Faranoush M, Zaker F, Safa M. Inhibition of Skp2 enhances doxorubicin-induced cell death in B cell precursor acute lymphoblastic leukemia. Cell Biol Int. 2022 Jun;46(6):895-906. doi: 10.1002/cbin.11779. Epub 2022 Mar 13. PMID: 35143089. 7: Wu J, Su HK, Yu ZH, Xi SY, Guo CC, Hu ZY, Qu Y, Cai HP, Zhao YY, Zhao HF, Chen FR, Huang YF, To ST, Feng BH, Sai K, Chen ZP, Wang J. Skp2 modulates proliferation, senescence and tumorigenesis of glioma. Cancer Cell Int. 2020 Mar 6;20:71. doi: 10.1186/s12935-020-1144-z. PMID: 32165861; PMCID: PMC7059397. 8: Mikamo M, Kitagawa K, Sakai S, Uchida C, Ohhata T, Nishimoto K, Niida H, Suzuki S, Nakayama KI, Inui N, Suda T, Kitagawa M. Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis. Int J Mol Sci. 2018 Feb 6;19(2):474. doi: 10.3390/ijms19020474. PMID: 29415439; PMCID: PMC5855696.